Keyword: Otsuka Pharmaceutical
Cancer drugmakers cut prices by 56.7% for China; Celltrion's Rituxan biosim wins FDA panel support; Otsuka renews digital pill deal with Proteus.
Aurobindo buys parts of Sandoz for $1B; an ex-GSK scientist admits to stealing trade secrets; Lilly and Chi-Med's Chinese-made drug makes history.
Get ready for Otsuka's Abilify MyCite, the first "smart pill," to make its way to medicine cabinets, thanks to a pilot rollout with Magellan Health.
Shire could fill Takeda's gap of late-stage assets; GSK lays off 1,000 as a Bangladesh plant nears closure; Laekna gets two Novartis cancer drugs.
Biogen and Eisai's anti-amyloid candidate shows promise; Otsuka signs two M&A deals; Samsung BioLogics faces criminal probe over Biogen JV agreement.
Though she has spent most of her career in oncology, Deborah Dunsire, M.D., says she doesn't plan to expand Lundbeck outside of neuroscience.
Pfizer exits a JV with China's Hisun Pharma, FDA approved the first digital medicine, and Astellas was added to a charity donation probe.
The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.
Big Pharma companies largely enjoyed a nice first-half jump in value.
Orphan drug sales have nearly doubled since 2008, a trend set to continue through 2022 as companies increasingly focus on rare disease meds.